GSK reports positive lung cancer data; AZ breast cancer drug fails trial

GSK announced late-stage data showing efficacy for two drugs in lung cancer, while AstraZeneca's breast cancer candidate failed a key trial. The results are company-specific and do not alter the broader oncology landscape, but they may affect the respective companies' pipelines and market positions.